ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) was up 9% in pre-market trading this morning following positive data from its CD19-specifict CAR T-cell therapy programs. The therapies infuse T cells that are genetically modified to express a CD19-specific chimeric antigen receptor (CAR). The positive results demonstrated long term survival rates in patients with advanced non-Hodgkin lymphoma and with advanced acute lymphoblastic leukemia. According to TipRanks’ statistics, out of the 2 analysts who have rated ZIOP in the last 3 months, 1 gave a Buy while 1 remains on the sidelines. The average 12-month price target for the stock is $21, marking a 109% upside from where shares last closed.

ZIOP Consensus

Chipotle Mexican Grill, Inc. (NYSE:CMG) fell 5% in pre-market trading this morning after yesterday’s news that 28 Boston College students fell ill after eating at the restaurant. Although these cases are not confirmed to be E. Coli, this news follows reports that the illness has spread to more states an infected 52 people. Chipotle has since closed the restaurant in question to further investigate the matter with local health officials. According to TipRanks’ statistics, out of the 24 analysts who have rated CMG in the last 3 months, 12 gave a Buy rating, 1 gave a Sell rating, while 11 remain on the sidelines. The average 12-month price target for the stock is $608.88, marking a 10% upside from where shares last closed.

CMG Consensus

FireEye Inc (NASDAQ:FEYE) increased nearly 4% in pre-market trading up to $20.99. Walter Pritchard, an analyst for Citi, upgraded the company from Neutral to Buy after his firm’s survey indicated that there will be an increase in money spent in the cyber security sector in the coming year. He has raised his price target from $31 to $35, noting that the company demonstrates “exceptional strength.” Furthermore, the company released new research in which it identifies a threat. FireEye has pinned F1N1 as the hacker group responsible for stealing data from financial organizations. This development comes months after Mandiant Consulting initially identified a “financially motivated threat group.” According to the 17 analysts polled by TipRanks in the last 3 months, 6 are bullish on FEYE and 11 remain on the sidelines. The average 12-month price target for the company is $33.36, marking a 65% potential upside from where shares last closed.

FEYE Consensus

 

TherapeuticsMD Inc (NYSEMKT:TXMD) shot up 38% in pre-market trading up to $9.01 following yesterday afternoon’s announcement of positive top-line results for Phase 3 testing of TX-004HR, an investigational treatment for dyspareunia, or vaginal pain during sexual intercourse. All three doses of the treatment demonstrated positive results. In light of the development, Chris Howerton of Jefferies reiterated a Buy rating on the company and raised his price target from $15 to $18. The analyst estimates that peak sales for the drug could reach $1 billion. According to TipRanks, both analysts covering the stock recommend to Buy with an average 12-month price target of $16.50, marking a 152% potential upside from where shares last closed.

TXMD Consensus